RT Journal Article
SR Electronic
T1 Early signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.30.21268560
DO 10.1101/2021.12.30.21268560
A1 Christensen, Paul A.
A1 Olsen, Randall J.
A1 Long, S. Wesley
A1 Snehal, Richard
A1 Davis, James J.
A1 Saavedra, Matthew Ojeda
A1 Reppond, Kristina
A1 Shyer, Madison N.
A1 Cambric, Jessica
A1 Gadd, Ryan
A1 Thakur, Rashi M.
A1 Batajoo, Akanksha
A1 Mangham, Regan
A1 Pena, Sindy
A1 Trinh, Trina
A1 Kinskey, Jacob C.
A1 Williams, Guy
A1 Olson, Robert
A1 Gollihar, Jimmy
A1 Musser, James M.
YR 2022
UL http://medrxiv.org/content/early/2022/01/04/2021.12.30.21268560.abstract
AB Genetic variants of SARS-CoV-2 continue to dramatically alter the landscape of the COVID-19 pandemic. The recently described variant of concern designated Omicron (B.1.1.529) has rapidly spread worldwide and is now responsible for the majority of COVID-19 cases in many countries. Because Omicron was recognized very recently, many knowledge gaps exist about its epidemiology, clinical severity, and disease course. A comprehensive genome sequencing study of SARS-CoV-2 in the Houston Methodist healthcare system identified 1,313 symptomatic patients with infections caused by Omicron from late November 2021 through December 20, 2021. Omicron very rapidly increased in only three weeks to cause 90% of all new COVID-19 cases. Compared to patients infected with either Alpha or Delta variants in our healthcare system, Omicron patients were significantly younger, had significantly increased vaccine breakthrough rates, and were significantly less likely to be hospitalized. Omicron patients required less intense respiratory support and had a shorter length of hospital stay, consistent with decreased disease severity. Although the number of Omicron patients we studied is relatively small, in the aggregate the data document the unusually rapid spread and increased occurrence of COVID-19 caused by the Omicron variant in metropolitan Houston, and provide information about disease character.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by the Houston Methodist Academic Institute Infectious Diseases Fund; and supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076 (J.J.D. and R.O.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Houston Methodist Research institutional review board (IRB1010-0199).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome data used in this study have been deposited to GISAID. https://www.gisaid.org